Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2007 1
2008 1
2009 1
2011 1
2013 1
2015 1
2016 2
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Kazda CM, et al. Among authors: shi c. Diabetes Care. 2016 Nov;39(11):e199-e200. doi: 10.2337/dci16-0030. Diabetes Care. 2016. PMID: 27926898 No abstract available.
Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, Berezin RH, Lahue BJ, Clark MA, Lacey MJ, Russell ME, Ellis SG, Hermiller JB, Cox DA, Cohen DJ; TAXUS-IV Investigators. Bakhai A, et al. Among authors: shi c. J Am Coll Cardiol. 2006 Jul 18;48(2):253-61. doi: 10.1016/j.jacc.2006.02.063. Epub 2006 Jun 22. J Am Coll Cardiol. 2006. PMID: 16843171 Free article.
Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.
Chen J, Shi C, Mahoney EM, Dunn ES, Rinfret S, Caro JJ, O'Brien J, El-Hadi W, Bhatt DL, Topol EJ, Cohen DJ. Chen J, et al. Among authors: shi c. Can J Cardiol. 2011 Mar-Apr;27(2):222-31. doi: 10.1016/j.cjca.2010.12.021. Can J Cardiol. 2011. PMID: 21459271 Clinical Trial.
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Kazda CM, et al. Among authors: shi c. Diabetes Care. 2017 Jun;40(6):808. doi: 10.2337/dc17-er06. Epub 2017 Apr 18. Diabetes Care. 2017. PMID: 28420698 Free PMC article. No abstract available.
Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ; ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators. Pinto DS, et al. Among authors: shi c. J Am Coll Cardiol. 2008 Nov 25;52(22):1758-68. doi: 10.1016/j.jacc.2008.08.021. J Am Coll Cardiol. 2008. PMID: 19022155 Free article. Clinical Trial.
Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP Jr, Zidar JP, Kuntz RE; SIRIUS Investigators. Cohen DJ, et al. Among authors: shi c. Circulation. 2004 Aug 3;110(5):508-14. doi: 10.1161/01.CIR.0000136821.99814.43. Epub 2004 Jul 19. Circulation. 2004. PMID: 15262844 Clinical Trial.
Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial.
Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Clark MR, Cohen BM, Ellis SG, Coleman P, Hill C, Shi C, Cutlip DE, Kuntz RE, Moses JW. Weisz G, et al. Among authors: shi c. J Am Coll Cardiol. 2006 Apr 4;47(7):1350-5. doi: 10.1016/j.jacc.2005.11.077. Epub 2006 Mar 20. J Am Coll Cardiol. 2006. PMID: 16580520 Free article.
12 results